NYSE:PENPenumbra Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Penumbra Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $191.87 -1.69 (-0.87 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$189.80Now: $191.87▼$193.0050-Day Range$166.88MA: $176.92▼$193.9852-Week Range$121.80Now: $191.87▼$195.00Volume137,200 shsAverage Volume244,652 shsMarket Capitalization$6.73 billionP/E Ratio176.03Dividend YieldN/ABeta0.64 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingPenumbra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $194.00, Penumbra has a potential upside of 1.1% from its current price of $191.87.Amount of Analyst CoveragePenumbra has only been the subject of 2 research reports in the past 90 days. Previous Next 3.8 Community Rank Outperform VotesPenumbra has received 699 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPenumbra has received 229 “underperform” votes. (Add your “underperform” vote.)Community SentimentPenumbra has received 75.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote “Outperform” if you believe PEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPenumbra does not currently pay a dividend.Dividend GrowthPenumbra does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,227,702.00 in company stock.Percentage Held by InsidersOnly 8.90% of the stock of Penumbra is held by insiders.Percentage Held by Institutions83.77% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Penumbra are expected to grow in the coming year, from ($0.09) to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Penumbra is 176.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Penumbra is 176.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.65.Price to Book Value per Share RatioPenumbra has a P/B Ratio of 13.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:PEN Previous Symbol CUSIPN/A CIK1321732 Webwww.penumbrainc.com Phone510-748-3200Debt Debt-to-Equity Ratio0.15 Current Ratio5.15 Quick Ratio3.27Price-To-Earnings Trailing P/E Ratio176.03 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$547.41 million Price / Sales12.29 Cash Flow$1.25 per share Price / Cash Flow153.32 Book Value$13.91 per share Price / Book13.79Profitability EPS (Most Recent Fiscal Year)$0.98 Net Income$48.46 million Net Margins7.04% Return on Equity5.72% Return on Assets4.28%Miscellaneous Employees2,700 Outstanding Shares35,070,000Market Cap$6.73 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable PEN Rates by TradingView Receive PEN News and Ratings via Email Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Penumbra (NYSE:PEN) Frequently Asked Questions How has Penumbra's stock been impacted by COVID-19 (Coronavirus)? Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PEN stock has increased by 8.5% and is now trading at $191.87. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Penumbra? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra. When is Penumbra's next earnings date? Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Penumbra. How were Penumbra's earnings last quarter? Penumbra Inc (NYSE:PEN) posted its earnings results on Thursday, May, 7th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.10 by $0.06. The company had revenue of $137.33 million for the quarter, compared to analyst estimates of $136.28 million. Penumbra had a return on equity of 5.72% and a net margin of 7.04%. The business's quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the company earned $0.23 earnings per share. View Penumbra's earnings history. What price target have analysts set for PEN? 5 equities research analysts have issued 1-year price objectives for Penumbra's stock. Their forecasts range from $180.00 to $214.00. On average, they expect Penumbra's share price to reach $194.00 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View analysts' price targets for Penumbra. Has Penumbra been receiving favorable news coverage? News articles about PEN stock have been trending very negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Penumbra earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Penumbra. Are investors shorting Penumbra? Penumbra saw a drop in short interest in June. As of June 30th, there was short interest totaling 2,800,000 shares, a drop of 8.2% from the June 15th total of 3,050,000 shares. Based on an average daily trading volume, of 259,500 shares, the days-to-cover ratio is currently 10.8 days. Currently, 8.4% of the company's stock are sold short. View Penumbra's Current Options Chain. Who are some of Penumbra's key competitors? Some companies that are related to Penumbra include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Tandem Diabetes Care (TNDM), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA) and Inari Medical (NARI). View all competitors. What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), AbbVie (ABBV), DexCom (DXCM), Intuitive Surgical (ISRG), Medtronic (MDT), Boeing (BA), salesforce.com (CRM) and Gilead Sciences (GILD). Who are Penumbra's key executives? Penumbra's management team includes the following people: Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41) What is Penumbra's stock symbol? Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN." Who are Penumbra's major shareholders? Penumbra's stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.02%) and Diversified Trust Co (0.01%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View institutional ownership trends for Penumbra. Which major investors are buying Penumbra stock? PEN stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Diversified Trust Co. View insider buying and selling activity for Penumbra. How do I buy shares of Penumbra? Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Penumbra's stock price today? One share of PEN stock can currently be purchased for approximately $191.87. How big of a company is Penumbra? Penumbra has a market capitalization of $6.73 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe. What is Penumbra's official website? The official website for Penumbra is www.penumbrainc.com. How can I contact Penumbra? Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
